NEUROTECH INTERNATIONAL LIMITED - Announcements

Market Cap $79.35M Add to my watchlist

Healthcare Medical Devices

Neurotech International Limited is an Australia-based clinical-stage biopharmaceutical... Neurotech International Limited is an Australia-based clinical-stage biopharmaceutical development company. The Company is focused on the development and commercialization of neurological solutions focused predominately on pediatric neurological disorders. The Company conducts clinical studies to assess the neuro-protective, anti-inflammatory, and neuro-modulatory activities of its NTI/Dolce cannabis strains. It is also commercializing Mente, a home therapy to increase engagement and improve relaxation in autistic children with elevated delta-band brain activity. Its product, Mente Autism, assists with the management of children with autism spectrum disorder (ASD). Its development program NTI164 completed a Phase I/II clinical trial to treat patients with autism spectrum disorder (ASD). Mente Autism is a portable, electroencephalographic (EEG) medical device for home use in the form of a headband that uses closed-loop neurofeedback to helo-relax the minds of children with ASD. More

HELPING PATIENTS ON THEIR JOURNEY TO BETTER HEALTH

Combining science, nature and human compassion, Little Green Pharma (ASX:LGP) are committed to improving the quality of life for sufferers of debilitating chronic conditions. NEWS: Little Green Pharma shares surge as Germany legalises Cannabis.

Announcements

Filter Results

All Price Sensitive Only

NTI	Notice of Change of Auditor		08/05/24	83.71KB	Share
NTI	Change of Director's Interest Notice		08/05/24	1.08MB	Share
NTI	Investor Webinar on Rett Syndrome Clinical Trial Results		06/05/24	85.16KB	Share
NTI	Investor Presentation		06/05/24	1.77MB	Share
NTI	Rett Syndrome Phase I/II trial shows significant benefits	PRICE SENSITIVE	06/05/24	593.85KB	Share
NTI	Trading Halt	PRICE SENSITIVE	03/05/24	140.26KB	Share
NTI	Neurotech Receives $10 Million in Placement Funds		24/04/24	83.91KB	Share
NTI	Notification regarding unquoted securities - NTI		24/04/24	17.64KB	Share
NTI	Secondary Trading Notice		24/04/24	91.73KB	Share
NTI	Application for quotation of securities - NTI		24/04/24	15.81KB	Share
NTI	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	23/04/24	445.81KB	Share
NTI	Initial Director's Interest Notice		19/04/24	125.34KB	Share
NTI	Final Director's Interest Notice		19/04/24	130.37KB	Share
NTI	Proposed issue of securities - NTI		19/04/24	16.84KB	Share
NTI	Board Changes		19/04/24	102.61KB	Share
NTI	Investor Presentation		17/04/24	2.32MB	Share
NTI	Proposed issue of securities - NTI		17/04/24	18.84KB	Share
NTI	Neurotech Completes $10 Million Capital Raise	PRICE SENSITIVE	17/04/24	193.4KB	Share
NTI	Positive Top-Line Rett Syndrome Clinical Trial Results	PRICE SENSITIVE	17/04/24	200.12KB	Share
NTI	Phase II/III ASD Trial Successfully Meets Primary Endpoint	PRICE SENSITIVE	17/04/24	361.07KB	Share
NTI	Investor Webinar on Clinical Trial Results		16/04/24	98.91KB	Share
NTI	Trading Halt	PRICE SENSITIVE	15/04/24	141.44KB	Share
NTI	Proposed issue of securities - NTI		10/04/24	19.39KB	Share
NTI	Strategic Partnership with Fenix Innovation Group		10/04/24	196.39KB	Share
NTI	Last Patient Completes Treatment in NTIASD2 Clinical Trial	PRICE SENSITIVE	10/04/24	183.31KB	Share
NTI	Change in substantial holding		27/03/24	289.69KB	Share
NTI	Appointment of Joint Company Secretary		21/03/24	76.78KB	Share
NTI	Neurotech Presentation at NWR Virtual Healthcare Conference		21/03/24	2.52MB	Share
NTI	Neurotech to present at NWR Virtual Healthcare Conference		19/03/24	98.59KB	Share
NTI	Secondary Trading Notice		15/03/24	91.99KB	Share
NTI	Notification regarding unquoted securities - NTI		15/03/24	14.66KB	Share
NTI	Application for quotation of securities - NTI		15/03/24	15.68KB	Share
NTI	NTI to Present at Spark Plus Conference in Singapore		13/03/24	2.59MB	Share
NTI	Rett Syndrome Patients to Receive NTI164 for 52 Weeks	PRICE SENSITIVE	13/03/24	180.94KB	Share
NTI	Notification of cessation of securities - NTI		12/03/24	14.65KB	Share
NTI	Secondary Trading Notice		11/03/24	91.98KB	Share
NTI	Notification regarding unquoted securities - NTI		08/03/24	14.99KB	Share
NTI	Application for quotation of securities - NTI		08/03/24	15.9KB	Share
NTI	Initial ESG Report		27/02/24	1.8MB	Share
NTI	Appendix 4D and Half Year Accounts	PRICE SENSITIVE	27/02/24	814.41KB	Share
NTI	Investor Presentation		21/02/24	2.39MB	Share
NTI	PANDAS/PANS Patients Show Continued Clinical Improvement	PRICE SENSITIVE	21/02/24	325.1KB	Share
NTI	Secondary Trading Notice		14/02/24	93.56KB	Share
NTI	Notification regarding unquoted securities - NTI		14/02/24	14.99KB	Share
NTI	Application for quotation of securities - NTI		14/02/24	15.91KB	Share
NTI	Neurotech Receives Additional HREC Approval in Autism	PRICE SENSITIVE	13/02/24	114.1KB	Share
NTI	ASD Phase I/II Patients Exceed Treatment Beyond 90 Weeks		07/02/24	130.25KB	Share
NTI	Amended Change of Director's Interest Notice		30/01/24	233.81KB	Share
NTI	Change of Director's Interest Notice		30/01/24	150.24KB	Share
NTI	NTI Receives HREC Approval for Cerebral Palsy Trial	PRICE SENSITIVE	29/01/24	179.92KB	Share
NTI	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	24/01/24	583.12KB	Share
NTI	Secondary Trading Notice		22/01/24	91.57KB	Share
NTI	Application for quotation of securities - NTI		22/01/24	25.64KB	Share
NTI	Notification regarding unquoted securities - NTI		17/01/24	28.33KB	Share
NTI	Secondary Trading Notice		19/12/23	91.77KB	Share
NTI	Application for quotation of securities - NTI		19/12/23	24.91KB	Share
NTI	Phase II/III Autism Clinical Trial Completes Recruitment	PRICE SENSITIVE	19/12/23	178.77KB	Share
NTI	Change in substantial holding		05/12/23	291.25KB	Share
NTI	HREC Approval to Extend Phase II/III ASD Trial to Adults	PRICE SENSITIVE	04/12/23	175.52KB	Share
NTI	Change of Director's Interest Notice x 2		01/12/23	329.86KB	Share
NTI	Application for quotation of securities - NTI		30/11/23	24.93KB	Share
NTI	Investor Presentation		22/11/23	2.34MB	Share
NTI	New Constitution		15/11/23	603.29KB	Share
NTI	Results of Meeting		15/11/23	103.44KB	Share
NTI	2023 Annual General Meeting Presentation		15/11/23	1.89MB	Share
NTI	Chairman's Address to 2023 Annual General Meeting		15/11/23	111.09KB	Share
NTI	Neurotech Receives $3.17 Million R&D Tax Incentive Refund	PRICE SENSITIVE	14/11/23	105.98KB	Share
NTI	Q&A on Phase I/II PANDAS/PANS Clinical Trial Results		01/11/23	169.14KB	Share
NTI	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	27/10/23	396.35KB	Share
NTI	Notice of Quarterly Investor Conference Call		24/10/23	101.25KB	Share
NTI	Notice of Annual General Meeting/Proxy Form		16/10/23	626.33KB	Share
NTI	Investor Presentation - PANDAS/PANS Clinical Trials Results		06/10/23	1.58MB	Share
NTI	Phase I/II PANDAS/PANS Clinical Trial Meets Primary Endpoint	PRICE SENSITIVE	06/10/23	202.18KB	Share
NTI	Trading Halt	PRICE SENSITIVE	04/10/23	503.7KB	Share
NTI	Completion of Patient Recruitment in NTIRTT1 Clinical Trial	PRICE SENSITIVE	26/09/23	186.34KB	Share
NTI	Annual Report (Typeset)		22/09/23	6.67MB	Share
NTI	Secondary Trading Notice		18/09/23	93.51KB	Share
NTI	Application for quotation of securities - NTI		18/09/23	25.51KB	Share
NTI	Proposed issue of securities - NTI		15/09/23	24.56KB	Share
NTI	Clinician Briefing Presentation and Webcast		15/09/23	1.78MB	Share
NTI	Proposed issue of securities - NTI		15/09/23	31.63KB	Share
NTI	Appointment of Corporate Advisor		15/09/23	93.81KB	Share
NTI	Upcoming Clinician Briefing		11/09/23	161.9KB	Share
NTI	Last Patient Completes Treatment in NTIPANS1 Clinical Trial	PRICE SENSITIVE	31/08/23	141.88KB	Share
NTI	Appendix 4G and Corporate Governance Statement		30/08/23	375.23KB	Share
NTI	Appendix 4E & Annual Report	PRICE SENSITIVE	30/08/23	1.16MB	Share
NTI	Application for quotation of securities - NTI		08/08/23	24.86KB	Share
NTI	Proposed issue of securities - NTI		04/08/23	24.68KB	Share
NTI	Disclosure Document		04/08/23	310.97KB	Share
NTI	First Patient Treated in Rett Syndrome Clinical Trial	PRICE SENSITIVE	01/08/23	181.29KB	Share
NTI	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	26/07/23	321.97KB	Share
NTI	Notice of Quarterly Investor Conference Call		19/07/23	138.69KB	Share
NTI	NTI Receives HREC Approval for Rett Syndrome Clinical Trial	PRICE SENSITIVE	10/07/23	213.2KB	Share
NTI	Notification of cessation of securities - NTI		30/06/23	22.47KB	Share
NTI	Notification regarding unquoted securities - NTI		28/06/23	43.13KB	Share
NTI	NTI to Present at Rett Syndrome Foundation Meeting		05/06/23	120.49KB	Share
NTI	Results of Meeting		01/06/23	102.52KB	Share
NTI	NTI Granted 2 Year Extension of Treatment for ASD Patients	PRICE SENSITIVE	31/05/23	188.33KB	Share
NTI	NTI granted HREC Approval for PANDAS/PANS Trial Extension	PRICE SENSITIVE	30/05/23	178.8KB	Share
NTI	Notification of cessation of securities - NTI		16/05/23	21.67KB	Share

NTI Notice of Change of Auditor
08/05/24		83.71KB	Share
NTI Change of Director's Interest Notice
08/05/24		1.08MB	Share
NTI Investor Webinar on Rett Syndrome Clinical Trial Results
06/05/24		85.16KB	Share
NTI Investor Presentation
06/05/24		1.77MB	Share
NTI Rett Syndrome Phase I/II trial shows significant benefits
06/05/24	PRICE SENSITIVE	593.85KB	Share
NTI Trading Halt
03/05/24	PRICE SENSITIVE	140.26KB	Share
NTI Neurotech Receives $10 Million in Placement Funds
24/04/24		83.91KB	Share
NTI Notification regarding unquoted securities - NTI
24/04/24		17.64KB	Share
NTI Secondary Trading Notice
24/04/24		91.73KB	Share
NTI Application for quotation of securities - NTI
24/04/24		15.81KB	Share
NTI Quarterly Activities/Appendix 4C Cash Flow Report
23/04/24	PRICE SENSITIVE	445.81KB	Share
NTI Initial Director's Interest Notice
19/04/24		125.34KB	Share
NTI Final Director's Interest Notice
19/04/24		130.37KB	Share
NTI Proposed issue of securities - NTI
19/04/24		16.84KB	Share
NTI Board Changes
19/04/24		102.61KB	Share
NTI Investor Presentation
17/04/24		2.32MB	Share
NTI Proposed issue of securities - NTI
17/04/24		18.84KB	Share
NTI Neurotech Completes $10 Million Capital Raise
17/04/24	PRICE SENSITIVE	193.4KB	Share
NTI Positive Top-Line Rett Syndrome Clinical Trial Results
17/04/24	PRICE SENSITIVE	200.12KB	Share
NTI Phase II/III ASD Trial Successfully Meets Primary Endpoint
17/04/24	PRICE SENSITIVE	361.07KB	Share
NTI Investor Webinar on Clinical Trial Results
16/04/24		98.91KB	Share
NTI Trading Halt
15/04/24	PRICE SENSITIVE	141.44KB	Share
NTI Proposed issue of securities - NTI
10/04/24		19.39KB	Share
NTI Strategic Partnership with Fenix Innovation Group
10/04/24		196.39KB	Share
NTI Last Patient Completes Treatment in NTIASD2 Clinical Trial
10/04/24	PRICE SENSITIVE	183.31KB	Share
NTI Change in substantial holding
27/03/24		289.69KB	Share
NTI Appointment of Joint Company Secretary
21/03/24		76.78KB	Share
NTI Neurotech Presentation at NWR Virtual Healthcare Conference
21/03/24		2.52MB	Share
NTI Neurotech to present at NWR Virtual Healthcare Conference
19/03/24		98.59KB	Share
NTI Secondary Trading Notice
15/03/24		91.99KB	Share
NTI Notification regarding unquoted securities - NTI
15/03/24		14.66KB	Share
NTI Application for quotation of securities - NTI
15/03/24		15.68KB	Share
NTI NTI to Present at Spark Plus Conference in Singapore
13/03/24		2.59MB	Share
NTI Rett Syndrome Patients to Receive NTI164 for 52 Weeks
13/03/24	PRICE SENSITIVE	180.94KB	Share
NTI Notification of cessation of securities - NTI
12/03/24		14.65KB	Share
NTI Secondary Trading Notice
11/03/24		91.98KB	Share
NTI Notification regarding unquoted securities - NTI
08/03/24		14.99KB	Share
NTI Application for quotation of securities - NTI
08/03/24		15.9KB	Share
NTI Initial ESG Report
27/02/24		1.8MB	Share
NTI Appendix 4D and Half Year Accounts
27/02/24	PRICE SENSITIVE	814.41KB	Share
NTI Investor Presentation
21/02/24		2.39MB	Share
NTI PANDAS/PANS Patients Show Continued Clinical Improvement
21/02/24	PRICE SENSITIVE	325.1KB	Share
NTI Secondary Trading Notice
14/02/24		93.56KB	Share
NTI Notification regarding unquoted securities - NTI
14/02/24		14.99KB	Share
NTI Application for quotation of securities - NTI
14/02/24		15.91KB	Share
NTI Neurotech Receives Additional HREC Approval in Autism
13/02/24	PRICE SENSITIVE	114.1KB	Share
NTI ASD Phase I/II Patients Exceed Treatment Beyond 90 Weeks
07/02/24		130.25KB	Share
NTI Amended Change of Director's Interest Notice
30/01/24		233.81KB	Share
NTI Change of Director's Interest Notice
30/01/24		150.24KB	Share
NTI NTI Receives HREC Approval for Cerebral Palsy Trial
29/01/24	PRICE SENSITIVE	179.92KB	Share
NTI Quarterly Activities/Appendix 4C Cash Flow Report
24/01/24	PRICE SENSITIVE	583.12KB	Share
NTI Secondary Trading Notice
22/01/24		91.57KB	Share
NTI Application for quotation of securities - NTI
22/01/24		25.64KB	Share
NTI Notification regarding unquoted securities - NTI
17/01/24		28.33KB	Share
NTI Secondary Trading Notice
19/12/23		91.77KB	Share
NTI Application for quotation of securities - NTI
19/12/23		24.91KB	Share
NTI Phase II/III Autism Clinical Trial Completes Recruitment
19/12/23	PRICE SENSITIVE	178.77KB	Share
NTI Change in substantial holding
05/12/23		291.25KB	Share
NTI HREC Approval to Extend Phase II/III ASD Trial to Adults
04/12/23	PRICE SENSITIVE	175.52KB	Share
NTI Change of Director's Interest Notice x 2
01/12/23		329.86KB	Share
NTI Application for quotation of securities - NTI
30/11/23		24.93KB	Share
NTI Investor Presentation
22/11/23		2.34MB	Share
NTI New Constitution
15/11/23		603.29KB	Share
NTI Results of Meeting
15/11/23		103.44KB	Share
NTI 2023 Annual General Meeting Presentation
15/11/23		1.89MB	Share
NTI Chairman's Address to 2023 Annual General Meeting
15/11/23		111.09KB	Share
NTI Neurotech Receives $3.17 Million R&D Tax Incentive Refund
14/11/23	PRICE SENSITIVE	105.98KB	Share
NTI Q&A on Phase I/II PANDAS/PANS Clinical Trial Results
01/11/23		169.14KB	Share
NTI Quarterly Activities/Appendix 4C Cash Flow Report
27/10/23	PRICE SENSITIVE	396.35KB	Share
NTI Notice of Quarterly Investor Conference Call
24/10/23		101.25KB	Share
NTI Notice of Annual General Meeting/Proxy Form
16/10/23		626.33KB	Share
NTI Investor Presentation - PANDAS/PANS Clinical Trials Results
06/10/23		1.58MB	Share
NTI Phase I/II PANDAS/PANS Clinical Trial Meets Primary Endpoint
06/10/23	PRICE SENSITIVE	202.18KB	Share
NTI Trading Halt
04/10/23	PRICE SENSITIVE	503.7KB	Share
NTI Completion of Patient Recruitment in NTIRTT1 Clinical Trial
26/09/23	PRICE SENSITIVE	186.34KB	Share
NTI Annual Report (Typeset)
22/09/23		6.67MB	Share
NTI Secondary Trading Notice
18/09/23		93.51KB	Share
NTI Application for quotation of securities - NTI
18/09/23		25.51KB	Share
NTI Proposed issue of securities - NTI
15/09/23		24.56KB	Share
NTI Clinician Briefing Presentation and Webcast
15/09/23		1.78MB	Share
NTI Proposed issue of securities - NTI
15/09/23		31.63KB	Share
NTI Appointment of Corporate Advisor
15/09/23		93.81KB	Share
NTI Upcoming Clinician Briefing
11/09/23		161.9KB	Share
NTI Last Patient Completes Treatment in NTIPANS1 Clinical Trial
31/08/23	PRICE SENSITIVE	141.88KB	Share
NTI Appendix 4G and Corporate Governance Statement
30/08/23		375.23KB	Share
NTI Appendix 4E & Annual Report
30/08/23	PRICE SENSITIVE	1.16MB	Share
NTI Application for quotation of securities - NTI
08/08/23		24.86KB	Share
NTI Proposed issue of securities - NTI
04/08/23		24.68KB	Share
NTI Disclosure Document
04/08/23		310.97KB	Share
NTI First Patient Treated in Rett Syndrome Clinical Trial
01/08/23	PRICE SENSITIVE	181.29KB	Share
NTI Quarterly Activities/Appendix 4C Cash Flow Report
26/07/23	PRICE SENSITIVE	321.97KB	Share
NTI Notice of Quarterly Investor Conference Call
19/07/23		138.69KB	Share
NTI NTI Receives HREC Approval for Rett Syndrome Clinical Trial
10/07/23	PRICE SENSITIVE	213.2KB	Share
NTI Notification of cessation of securities - NTI
30/06/23		22.47KB	Share
NTI Notification regarding unquoted securities - NTI
28/06/23		43.13KB	Share
NTI NTI to Present at Rett Syndrome Foundation Meeting
05/06/23		120.49KB	Share
NTI Results of Meeting
01/06/23		102.52KB	Share
NTI NTI Granted 2 Year Extension of Treatment for ASD Patients
31/05/23	PRICE SENSITIVE	188.33KB	Share
NTI NTI granted HREC Approval for PANDAS/PANS Trial Extension
30/05/23	PRICE SENSITIVE	178.8KB	Share
NTI Notification of cessation of securities - NTI
16/05/23		21.67KB	Share

REFRESH

1 2 3 4 5

(20min delay)
Last 7.8¢		Change 0.003(4.00%)		Mkt cap ! $79.35M

Open	High	Low	Value	Volume
7.6¢	7.8¢	7.5¢	$28.02K	369.2K

Buyers (Bids)

No.	Vol.	Price($)
1	45935	7.6¢

Sellers (Offers)

Price($)	Vol.	No.
7.8¢	155289	3

View Market Depth

No.	Vol.	Price($)
1	45935	0.076
2	154837	0.075
3	47432	0.074
3	249651	0.073
3	68687	0.072

Price($)	Vol.	No.
0.078	155289	3
0.079	451112	1
0.080	754857	3
0.081	48000	1
0.082	65000	2

Last trade - 16.10pm 16/05/2024 (20 minute delay)


Last 7.8¢		Change 0.003 ( 2.63 %)
Open	High	Low	Volume
7.8¢	7.8¢	7.5¢	140119
Last updated 15.53pm 16/05/2024 ?

NTI (ASX) Chart

NEUROTECH INTERNATIONAL LIMITED - Announcements

Announcements

Buyers (Bids)

Sellers (Offers)

Top Stories